An Observational Study to Characterize Human Milk From Mothers Delivering Term SGA and AGA Infants.
NCT ID: NCT02421445
Last Updated: 2019-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
142 participants
OBSERVATIONAL
2015-04-30
2018-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Study of Human-Milk Based Nutrition Versus Formula in Premature Infants
NCT00506584
Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet
NCT03839173
Feeding Bovine Colostrum to Preterm Infants
NCT02054091
The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants
NCT01881256
Growth of Infants With Cow's Milk Allergy Fed an Amino Acid-based Formula Containing Two Human Milk Oligosaccharides
NCT03661736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Primary Objective of the study is to characterize and quantify maternal milk composition from mothers of adequately nourished and under nourished status delivering term Small for Gestational Age (SGA) infants, compared to adequately-nourished and undernourished mothers delivering term Appropriate for Gestational Age (AGA) infants as defined in Fenton growth chart 2013.
The secondary objective of the study is-
1. Association of maternal milk components with dietary intake and nourishment status of the mother.
2. Associations of maternal and infant clinical parameters to maternal milk nutrients.
3. To explore and analyze additional functional milk components, such as triacylglycerol, cholesterols, carotenoids, vitamins, microbiota, peptide profile, microRNA, cytokines, growth factors and hormones.
The subject will enroll in the study after signing the Informed Consent Form after delivery the infants (i.e. term AGA \& term SGA) within 72 hours. Total Duration of the study for subject is 24 weeks. Sponsor will notify the end of study after 90 days of last subject last visit. Principal Investigator responsibility is to detect and document AE and SAE
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Mothers between 18 and 40 years of age inclusive, at the time of enrolment
3. Having decided to predominantly breast-feed their new born baby at least until 6 months of age
4. Having permanent residence at a maximum distance of 50km from the hospital/center of investigation for the duration of this study and being able to follow all the steps of this study
5. Willing to provide informed consent according to the requirements of local regulations.
Exclusion Criteria
2. Currently participating or having participated in an interventional clinical trial during the last 4 weeks prior to the beginning of this study
3. Having a BMI ≥ 25.0
4. Chewing tobacco, smoking or drinking alcohol (\> 1 glass per day), consuming illicit drugs during pregnancy or/and duration of the study
5. Presenting any disease or medical condition which might prevent breast-feeding or collecting the human milk samples or for which breast-feeding is contraindicated
6. Having diabetes or gestational diabetes mellitus
7. Presenting dietary problems/illnesses such as anorexia, bulimia and celiac disease
8. Subject unable to comply with study procedures or unable to come to hospital for the study visits.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Neelam Kler, Dr
Role: PRINCIPAL_INVESTIGATOR
Sir Ganga Ram Hospital, Delhi
Anil Kumar Sapare, DR
Role: PRINCIPAL_INVESTIGATOR
Muzumdar Shaw Medical Centre, Bengalore
Sarika Prasad, Dr
Role: PRINCIPAL_INVESTIGATOR
Aadithya Adhikari Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Muzumdar Shaw Medical Centre
Delhi, Bangalore, India
Aadithya Adhikari Hospital
Mysore, Karnataka, India
Sir Ganga Ram Hospital
New Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12.23 NRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.